The San Francisco-based start-up plans to get its first drug into trials this year
Analysis of drugs such as Ozempic finds a lower health risk for 42 conditions but a higher rate of disorders such as arthritis
Scorpion’s drug candidate inhibits a mutation that is a major driver of breast, gynaecological and head and neck cancers
Verdiva Bio wants to use potential drugs acquired in China to compete in growing obesity market
IDRx tests treatment for digestive system cancer that affects 4,000 to 6,000 people a year in US
Autolus hopes its less gruelling Car-T treatment for a type of leukaemia will allow it to compete with bigger rivals
Regulatory go-ahead marks latest boost for drugmaker’s blockbuster anti-obesity franchise
Treatment for short bowel syndrome fails to win approval from US regulator
Boss David Epstein hopes to replicate his success at Seagen after $43bn sale last year
Initial research has focused on obesity, but Ozempic, Wegovy and Mounjaro may potentially be used for addiction, heart disease and Alzheimer’s
Chris Boshoff played role in drugmaker’s acquisition of Seagen, which has been criticised by investor
Danish company expects data to show that CagriSema cuts weight by 25 per cent in just over a year
Acquisition is latest example of western drugmakers turning to China to tap innovation
Potential wider uses should maintain investor enthusiasm and fuel ongoing competition
Pharmaceutical companies turn to jurisdictions with simpler regulatory regimes
Analysis points to potential of drugs such as Ozempic beyond tackling obesity and diabetes
Drug company made claims even though a study of donanemab’s preventive potential is not due to end until 2027
CBO analysis says savings from other health benefits would not offset expense of weight-loss jabs
US biotech researches treatments to reduce muscle loss from blockbuster diet medicines
The company is thriving as weight-loss drugs boom, but investors see warning signs it has reached ‘peak enthusiasm’
Swiss pharma group is a high spender on R&D but has had misses in Alzheimer’s and cancer
Latest setback for Dato-DXd comes after disappointing results in lung cancer treatment earlier this month
Results offer hope of progress in combating bladder tumours and some forms of breast cancer
High rates of vomiting among those who took strong doses in trials have unsettled investors
Danish pharma company also unveils early data for closely watched oral pill to tackle weight loss